<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703881</url>
  </required_header>
  <id_info>
    <org_study_id>AY-ActaGain</org_study_id>
    <nct_id>NCT04703881</nct_id>
  </id_info>
  <brief_title>Tolerance and Acceptability Evaluation AYMES ActaGain</brief_title>
  <official_title>Tolerance and Acceptability Evaluation AYMES ActaGain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aymes International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aymes International Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate tolerance and acceptability of 'AYMES ActaGain' in patients requiring&#xD;
      supplementary oral nutritional support compared with currently available alternatives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate tolerance and acceptability of 'AYMES ActaGain' in patients requiring&#xD;
      supplementary oral nutritional support compared with currently available alternatives,&#xD;
      measuring outcomes of GI effects, Compliance, product preference, convenience etc.&#xD;
&#xD;
      To obtain data to support an ACBS submissions for 'AYMES ActaGain' (to allow for prescription&#xD;
      in the community at NHS expense).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastro-Intestinal Tolerance when consuming AYMES ActaGain</measure>
    <time_frame>30 days</time_frame>
    <description>To assess gastro-intestinal tolerance of 'AYMES ActaGain' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number of any GI complaints via a daily diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the acceptability of 'AYMES ActaGain' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink. A 5 point hedonic scale will be used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the acceptability of 'AYMES ActaGain' in patients in the community requiring oral nutritional supplementation. A daily compliance diary will be kept detailing compliance to prescription versus prescribed amount.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>AYMES ActaGain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks will be changed / started on an equivalent prescription of 'AYMES ActaGain' for a period of 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>AYMES ActaGain</intervention_name>
    <description>AYMES ActaGain is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is designed as a supplement to the diet but can also be used as a sole source of nutrition.</description>
    <arm_group_label>AYMES ActaGain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients.&#xD;
&#xD;
          -  ≥ 18 years of age.&#xD;
&#xD;
          -  Patients of the intended target group (e.g. MUST score ≥ 1, with or at risk of disease&#xD;
             related malnutrition) with an anticipated period of nutritional support ≥ 4 weeks.&#xD;
&#xD;
          -  Patient is able and willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with medical or dietary contraindication to any feed ingredients.&#xD;
&#xD;
          -  Patients requiring sole enteral tube feeding or parenteral nutrition.&#xD;
&#xD;
          -  Patients with chronic renal disease requiring dialysis.&#xD;
&#xD;
          -  Patients with liver failure.&#xD;
&#xD;
          -  Patients for whom the investigator has concerns regarding the ability or willingness&#xD;
             of the patient and or carer to comply with protocol requirements.&#xD;
&#xD;
          -  Patients assessed by a Speech and Language Therapist who require thickened fluids.&#xD;
&#xD;
          -  Participation in any other studies that may interfere with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AYMES International Ltd.</name>
      <address>
        <city>Haywards Heath</city>
        <zip>RH16 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

